A Singanayagam1, K Manalan1, D W Connell2, J D Chalmers3, S Sridhar2, A I Ritchie1, A Lalvani2, M Wickremasinghe1, O M Kon1. 1. Chest and Allergy Department, St Marys Hospital, Imperial College NHS Trust, London. 2. Chest and Allergy Department, St Marys Hospital, Imperial College NHS Trust, London, Tuberculosis Immunology Group, Imperial College London, London. 3. Tayside Respiratory Research Group, University of Dundee, Dundee, UK.
Abstract
OBJECTIVE: To evaluate C-reactive protein (CRP), globulin and white blood cell (WBC) count as predictors of treatment outcome in pulmonary tuberculosis (PTB). METHODS: An observational study of patients with active PTB was conducted at a tertiary centre. All patients had serum CRP, globulin and WBC measured at baseline and at 2 months following commencement of treatment. The outcome of interest was requirement for extension of treatment beyond 6 months. RESULTS: There were 226 patients included in the study. Serum globulin 45 g/l was the only baseline biomarker evaluated that independently predicted requirement for treatment extension (OR 3.42, 95%CI 1.597.32, P 0.001). An elevated globulin level that failed to normalise at 2 months was also associated with increased requirement for treatment extension (63.9% vs. 5.1%, P 0.001), and had a low negative likelihood ratio (0.07) for exclusion of requirement for treatment extension. On multivariable analysis, an elevated globulin that failed to normalise at 2 months was independently associated with requirement for treatment extension (OR 6.13, 95%CI 2.2316.80, P 0.001). CONCLUSIONS: Serum globulin independently predicts requirement for treatment extension in PTB and outperforms CRP and WBC as a predictive biomarker. Normalisation of globulin at 2 months following treatment commencement is associated with low risk of requirement for treatment extension.
OBJECTIVE: To evaluate C-reactive protein (CRP), globulin and white blood cell (WBC) count as predictors of treatment outcome in pulmonary tuberculosis (PTB). METHODS: An observational study of patients with active PTB was conducted at a tertiary centre. All patients had serum CRP, globulin and WBC measured at baseline and at 2 months following commencement of treatment. The outcome of interest was requirement for extension of treatment beyond 6 months. RESULTS: There were 226 patients included in the study. Serum globulin 45 g/l was the only baseline biomarker evaluated that independently predicted requirement for treatment extension (OR 3.42, 95%CI 1.597.32, P 0.001). An elevated globulin level that failed to normalise at 2 months was also associated with increased requirement for treatment extension (63.9% vs. 5.1%, P 0.001), and had a low negative likelihood ratio (0.07) for exclusion of requirement for treatment extension. On multivariable analysis, an elevated globulin that failed to normalise at 2 months was independently associated with requirement for treatment extension (OR 6.13, 95%CI 2.2316.80, P 0.001). CONCLUSIONS: Serum globulin independently predicts requirement for treatment extension in PTB and outperforms CRP and WBC as a predictive biomarker. Normalisation of globulin at 2 months following treatment commencement is associated with low risk of requirement for treatment extension.
Authors: Milena Lima de Moraes; Daniela Maria de Paula Ramalho; Karina Neves Delogo; Pryscila Fernandes Campino Miranda; Eliene Denites Duarte Mesquita; Hedi Marinho de Melo Guedes de Oliveira; Antônio Ruffino Netto; Marcelino José Dos Anjos; Afrânio Lineu Kritski; Martha Maria de Oliveira Journal: Biol Trace Elem Res Date: 2014-06-24 Impact factor: 3.738
Authors: M Hosp; A M Elliott; J G Raynes; A G Mwinga; N Luo; R Zangerle; J O Pobee; H Wachter; M P Dierich; K P McAdam; D Fuchs Journal: Lung Date: 1997 Impact factor: 2.584
Authors: A C Hesseling; G Walzl; D A Enarson; N M Carroll; K Duncan; P T Lukey; C Lombard; P R Donald; K A Lawrence; R P Gie; P D van Helden; N Beyers Journal: Int J Tuberc Lung Dis Date: 2010-05 Impact factor: 2.373
Authors: S Brahmbhatt; G F Black; N M Carroll; N Beyers; F Salker; M Kidd; P T Lukey; K Duncan; P van Helden; G Walzl Journal: Clin Exp Immunol Date: 2006-11 Impact factor: 4.330
Authors: Caian L Vinhaes; Deivide Oliveira-de-Souza; Paulo S Silveira-Mattos; Betania Nogueira; Ruiru Shi; Wang Wei; Xing Yuan; Guolong Zhang; Ying Cai; Clifton E Barry; Laura E Via; Kiyoshi F Fukutani; Bruno B Andrade; Katrin D Mayer-Barber Journal: Cytokine Date: 2019-06-18 Impact factor: 3.861
Authors: Cherry Kim; So Hee Park; Sang Young Oh; Sung-Soo Kim; Kyung-Wook Jo; Tae Sun Shim; Mi Young Kim Journal: PLoS One Date: 2017-03-27 Impact factor: 3.240
Authors: Anna Cristina C Carvalho; Gustavo Amorim; Mayla G M Melo; Ana Karla A Silveira; Pedro H L Vargas; Adriana S R Moreira; Michael S Rocha; Alexandra B Souza; María B Arriaga; Mariana Araújo-Pereira; Marina C Figueiredo; Betina Durovni; José R Lapa-E-Silva; Solange Cavalcante; Valeria C Rolla; Timothy R Sterling; Marcelo Cordeiro-Santos; Bruno B Andrade; Elisangela C Silva; Afrânio L Kritski Journal: Front Immunol Date: 2021-07-02 Impact factor: 7.561